1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,350 | 7,600 | 24.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | WUXI XDC (02268): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| Do | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| Di | BOCOMI Raises WUXI XDC's TP to HKD91 w/Higher Earnings Forecasts | 2 | AASTOCKS | ||
| Mo | M Stanley Keeps Overweight on WUXI XDC; Firm Proposes Takeover Bid for BIODLINK-B | 3 | AASTOCKS | ||
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| Mo | CMBI Raises WUXI XDC's TP to HKD88 w/Rating Reiterated Buy; Earnings Expected to Grow Strongly | 2 | AASTOCKS | ||
| 15.01. | EQS Newswire: Gelonghui: WuXi XDC issues positive profit alert, to acquire BioDlink in bid to strengthen ADC CDMO lead | 445 | EQS Group (EN) | EQS Newswire / 15/01/2026 / 12:50 UTC+8
January 14, 2026 - WuXi XDC has issued a positive profit alert for fiscal 2025 and announced a cash tender offer for BioDlink, whose shares were suspended... ► Artikel lesen | |
| 15.01. | BIODLINK-B Surges 57% on Takeover Bid by WUXI XDC at 60% Premium | 7 | AASTOCKS | ||
| 14.01. | WUXI XDC (02268): INSIDE INFORMATION PRESENTATION AT 2026 ANNUAL HEALTHCARE CONFERENCE | - | HKEx | ||
| 14.01. | WUXI XDC (02268): JOINT ANNOUNCEMENT (1) VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ... | - | HKEx | ||
| 14.01. | WUXI XDC (02268): POSITIVE PROFIT ALERT | 1 | HKEx | ||
| 13.01. | CMBI Expects LT Continuation of Innovative Drug Export Trend, Rates SINO BIOPHARM/WUXI XDC/Others at Buy | 4 | AASTOCKS | ||
| 13.01. | UBS Reiterates Buy on WUXI XDC; Last Yr's Newly Added Projects Beat Forecast | 1 | AASTOCKS | ||
| 23.12.25 | Akari begins GMP manufacturing of lead ADC program with WuXi XDC | 3 | Investing.com | ||
| 23.12.25 | Akari startet GMP-Produktion für führendes ADC-Programm mit WuXi XDC | 1 | Investing.com Deutsch | ||
| 12.12.25 | WUXI XDC (02268): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 12, 2025 | 1 | HKEx | ||
| 01.12.25 | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 25.11.25 | WUXI XDC (02268): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, DECEMBER 12, 2025 | 1 | HKEx | ||
| 25.11.25 | WUXI XDC (02268): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 25.11.25 | WUXI XDC (02268): CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAP FOR THE EXISTING ANTIBODIES MASTER SERVICES AGREEMENT (2) RENEWAL OF THE ... | 2 | HKEx | ||
| 25.11.25 | WUXI XDC (02268): CLOSURE OF REGISTER OF MEMBERS | - | HKEx |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 53,81 | -3,65 % | What Analysts Are Saying About CG Oncology Stock | ||
| APOGEE THERAPEUTICS | 70,02 | -12,32 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| QIAGEN | 46,130 | +0,01 % | AKTIE IM FOKUS: Qiagen schnellen zum Handelsschluss hoch - Strategische Optionen | FRANKFURT (dpa-AFX) - Die Papiere von Qiagen sind zum Börsenschluss am Dienstag nach oben geschnellt. Mit der Schlussauktion auf Xetra stiegen sie um 12,4 Prozent auf 44,11 Euro und waren damit im... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,680 | -7,21 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| IMMUNOME | 25,870 | +0,19 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| SUMMIT THERAPEUTICS | 16,490 | -5,07 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| BEAM THERAPEUTICS | 31,560 | -7,88 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| PRAXIS PRECISION MEDICINES | 311,12 | +2,21 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| ALUMIS | 24,520 | -6,70 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| BIONTECH | 98,10 | -0,05 % | Black Monday: Trotz Grönland, Strafzölle und Mercosur, BioTech im Aufwind! Bayer, Vidac Pharma; BioNTech und Novo Nordisk | Die Börse hat das Jahr 2026 sehr volatil begonnen. Nun gibt es wegen der offenen Grönlandfrage sogar wieder Strafzölle für europäische Staaten, die an der dänischen Verwaltung festhalten wollen. Fragen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,730 | -4,64 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 90,37 | -1,63 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| VERA THERAPEUTICS | 47,490 | -2,51 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 11,950 | -3,16 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| NUVALENT | 106,44 | -4,96 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen |
WUXI XDC CAYMAN INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 7,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.